Side-by-side comparison of AI visibility scores, market position, and capabilities
Chicago virtual care for ALS, Alzheimer's, and Parkinson's patients across 50 states; YC $46.3M B Capital/Google Ventures/CommonSpirit-backed as CMS GUIDE dementia provider competing with specialty neurology for neurodegenerative disease management.
Synapticure is a Chicago, Illinois-based virtual care company — backed by Y Combinator with $46.3 million raised including a $25 million Series A led by B Capital in November 2024, with prior investment from CommonSpirit Health, CVS Health Ventures, RA Capital, Google Ventures, Optum Ventures, and Rock Health — providing patients with ALS, Alzheimer's disease, Parkinson's disease, frontotemporal dementia (FTD), Huntington's disease, and other neurodegenerative conditions with specialized virtual neurology care, genetic counseling, AI-powered diagnostic support, care coordination, and 24/7 patient and caregiver support across all 50 US states. Synapticure serves as a nationwide CMS GUIDE (Guiding an Improved Dementia Experience) model provider for Alzheimer's patients — a Centers for Medicare & Medicaid Services innovation program that provides reimbursement for comprehensive dementia care management outside of traditional fee-for-service neurology visits.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.